Wavegate Corporation Announces $26 Million Series A Funding Round Led by UCEA Capital Partners Ltd. Lake Charles, Louisiana, USA – [December 10, 2024] – Wavegate Corporation, a pioneering developer of neuromodulation technology for chronic pain management, has secured a lead investor in their $26 million Series A funding round led by UCEA Capital Partners Ltd., a London-based investment firm. This financing will accelerate the development of Wavegate’s proprietary Ellipse™ platform, featuring StimuLux™ technology, designed to provide breakthrough therapeutic solutions for chronic pain patients. Wavegate’s Ellipse™ spinal cord stimulator uses optical reflectometry to provide closed-loop adaptive modulation, uniquely adjusting stimulation in real-time based on spinal cord movement. This technology, which received FDA Breakthrough Device designation, offers significant potential to improve the lives of chronic pain sufferers by maintaining consistent pain relief across a range of patient activities using either paresthesia-based or paresthesia-free neuromodulation. Wavegate also recently achieved successful first-in-human data, further validating the clinical promise of its Ellipse™ platform. “Securing this funding represents a pivotal moment for Wavegate as we continue to push the boundaries in neuromodulation technology,” said Dr. Erich Wolf, CEO of Wavegate Corporation. “UCEA’s investment validates the potential of our innovations and supports our vision of advancing effective, patient-centered pain management solutions.” The investment by UCEA Capital Partners aligns with its strategic focus on supporting transformative healthcare technologies. “Wavegate’s approach to neuromodulation reflects exactly the type of high-impact, innovation-driven opportunity we seek to champion. We are thrilled to support their journey in addressing a critical area of unmet medical need,” noted Joao Teixeira, Chairman of UCEA Capital Partners Ltd. The Series A funding will be instrumental in expanding Wavegate’s R&D efforts, clinical trials, and preparations for regulatory approvals, marking a significant step forward for the company as it progresses toward commercialization.

LAKE CHARLES, La., Jan. 13, 2022 /PRNewswire/ -- Wavegate Corporation announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Device designation for its StimuLux™ optical reflectometry system for closed-loop adaptive modulation of spinal cord stimulation. The FDA's Breakthrough Device designation is designed to expedite the development and regulatory review of medical devices that are intended to treat serious or life-threatening diseases. To qualify for this designation, preliminary evidence must demonstrate a reasonable expectation that the device will provide improved effectiveness compared to the standard of care. "We are pleased the FDA has granted Breakthrough Device designation for our novel StimuLux™ technology. This underscores the urgent need within our society for more effective treatments of chronic, debilitating pain," said Erich Wolf, MD, PhD, Chief Executive Officer. "We are eager to closely collaborate with the FDA as Wavegate works toward advancing the state of the art." StimuLux™ is a component of Wavegate Corporation's Ellipse neuromodulation platform which integrates multiple patented technologies which aim to systematically address unmet clinical needs within the neuromodulation industry. CAUTION: StimuLux™ optical reflectometry is limited by Federal Law to investigational use only.

April 23, 2020- Lake Charles, LA. Wavegate Technologies, LLC, has been restructured as a Delaware C-corporation. This gives Wavegate Corporation additional flexibility in stock offerings to investors and provides a widely-accepted legal framework under Delaware law.

Wavegate is pleased to announce that Matt F. Thomas has joined Wavegate's Board of Directors. Matt brings deep domain experience to Wavegate, having served as the General Manager for Medtronic's Spinal Cord Stimulation business. Matt is a welcome addition to the senior management team at Wavegate and rounds out the executive experience required to navigate Wavegate's Ellipse platform to the best-in-class market leader. Matt Thomas has over 25 years of experience leading medical device businesses. He has broad experience in strategy, business development, marketing, sales & new product development. Prior to joining Cerapedics in 2020, Matt was Vice President & General Manager for Medtronic’s Spinal Cord Stimulation & Early Interventions pain business. Previously, Matt also led a turnaround of Medtronic’s Kyphon business, returning it to growth for the first time since the acquisition. He joined Medtronic in 2002 and also had leadership roles in spine, diabetes, and deep brain stimulation. Prior to Medtronic, he was a product manager with Sonic Innovations and founder of HyperX, a health care data services company. He has an MBA from Carnegie Mellon University, a BS in economics from the University of Utah and studied at Johns Hopkins University.